These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31465124)

  • 1. The transcription factor FOXM1 regulates the balance between proliferation and aberrant differentiation in head and neck squamous cell carcinoma.
    Roh V; Hiou-Feige A; Misetic V; Rivals JP; Sponarova J; Teh MT; Ferreira Lopes S; Truan Z; Mermod M; Monnier Y; Hess J; Tolstonog GV; Simon C
    J Pathol; 2020 Jan; 250(1):107-119. PubMed ID: 31465124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.
    Zhang B; Zhang Y; Zou X; Chan AW; Zhang R; Lee TK; Liu H; Lau EY; Ho NP; Lai PB; Cheung YS; To KF; Wong HK; Choy KW; Keng VW; Chow LM; Chan KK; Cheng AS; Ko BC
    J Pathol; 2017 Dec; 243(4):418-430. PubMed ID: 28862757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
    Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
    Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FoxM1 overexpression promotes cell proliferation and migration and inhibits apoptosis in hypopharyngeal squamous cell carcinoma resulting in poor clinical prognosis.
    Chen Y; Liu Y; Ni H; Ding C; Zhang X; Zhang Z
    Int J Oncol; 2017 Oct; 51(4):1045-1054. PubMed ID: 28848994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1-Mediated Regulation of Reactive Oxygen Species and Radioresistance in Oral Squamous Cell Carcinoma Cells.
    Takeshita H; Yoshida R; Inoue J; Ishikawa K; Shinohara K; Hirayama M; Oyama T; Kubo R; Yamana K; Nagao Y; Gohara S; Sakata J; Nakashima H; Matsuoka Y; Nakamoto M; Hirayama M; Kawahara K; Takahashi N; Hirosue A; Kuwahara Y; Fukumoto M; Toya R; Murakami R; Nakayama H
    Lab Invest; 2023 May; 103(5):100060. PubMed ID: 36801643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent evaluation of a FOXM1-based quantitative malignancy diagnostic system (qMIDS) on head and neck squamous cell carcinomas.
    Ma H; Dai H; Duan X; Tang Z; Liu R; Sun K; Zhou K; Chen H; Xiang H; Wang J; Gao Q; Zou Y; Wan H; Teh MT
    Oncotarget; 2016 Aug; 7(34):54555-54563. PubMed ID: 27409343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop.
    Yang H; Wen L; Wen M; Liu T; Zhao L; Wu B; Yun Y; Liu W; Wang H; Wang Y; Wen N
    Anticancer Drugs; 2018 Mar; 29(3):216-226. PubMed ID: 29360662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G; Schmitz S; El Baroudi M; Caignet X; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
    Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
    Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
    Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.
    Lakshmanachetty S; Balaiya V; High WA; Koster MI
    Mol Cancer Res; 2019 Jun; 17(6):1279-1293. PubMed ID: 30910837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.
    Jiang Y; Cao W; Wu K; Qin X; Wang X; Li Y; Yu B; Zhang Z; Wang X; Yan M; Xu Q; Zhang J; Chen W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):365. PubMed ID: 31429766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated RUNX1 is a prognostic biomarker for human head and neck squamous cell carcinoma.
    Feng X; Zheng Z; Wang Y; Song G; Wang L; Zhang Z; Zhao J; Wang Q; Lun L
    Exp Biol Med (Maywood); 2021 Mar; 246(5):538-546. PubMed ID: 33241710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of FOXM1-induced epigenetic markers for head and neck squamous cell carcinomas.
    Hwang S; Mahadevan S; Qadir F; Hutchison IL; Costea DE; Neppelberg E; Liavaag PG; Waseem A; Teh MT
    Cancer; 2013 Dec; 119(24):4249-58. PubMed ID: 24114764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosa-like differentiation of head and neck cancer cells is inducible and drives the epigenetic loss of cell malignancy.
    Oppel F; Gendreizig S; Martinez-Ruiz L; Florido J; López-Rodríguez A; Pabla H; Loganathan L; Hose L; Kühnel P; Schmidt P; Schürmann M; Neumann JM; Viyof Ful F; Scholtz LU; Ligum D; Brasch F; Niehaus K; Escames G; Busche T; Kalinowski J; Goon P; Sudhoff H
    Cell Death Dis; 2024 Oct; 15(10):724. PubMed ID: 39358322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma.
    Teh MT; Gemenetzidis E; Patel D; Tariq R; Nadir A; Bahta AW; Waseem A; Hutchison IL
    PLoS One; 2012; 7(3):e34329. PubMed ID: 22461910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RUVBL1 is an amplified epigenetic factor promoting proliferation and inhibiting differentiation program in head and neck squamous cancers.
    Lin D; Lin B; Bhanot H; Riou R; Abt NB; Rajagopal J; Saladi SV
    Oral Oncol; 2020 Dec; 111():104930. PubMed ID: 32745900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
    Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
    J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance and biological functions of chemokine CXCL3 in head and neck squamous cell carcinoma.
    Guan J; Weng J; Ren Q; Zhang C; Hu L; Deng W; Lu S; Dong X; Li W; Li Y; Wang W
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34870709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.
    Chi LH; Chang WM; Chang YC; Chan YC; Tai CC; Leung KW; Chen CL; Wu AT; Lai TC; Li YJ; Hsiao M
    Sci Rep; 2017 Aug; 7(1):9031. PubMed ID: 28831179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.